rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Peter F. Lebowitz

Director

Company insider

Files Form 4 as: Director, BridgeBio Oncology Therapeutics.

In numbers

Trades disclosed
4
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
1
Companies where not an officer
1
First trade
24 Mar 2026
Last trade
16 Jun 2026
Last filed
18 Jun 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
BBOT BridgeBio Oncology TherapeuticsDirector · Biotechnology · last 16 Jun 20260 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
16 Jun 2026filed 18 Jun 2026BBOT BridgeBio Oncology Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—7,289 at $0.00filing
16 Jun 2026filed 18 Jun 2026BBOT BridgeBio Oncology Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—7,289 at $0.00filing
24 Mar 2026filed 26 Mar 2026BBOT BridgeBio Oncology Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—63,350 at $0.00filing
24 Mar 2026filed 26 Mar 2026BBOT BridgeBio Oncology Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—63,350 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Idan ElmelechCOO & Principal Financial Ofcr · COO & Principal Financial Ofcr at BridgeBio Oncology Therapeutics, filing Form 4 there in the last year
Marc CoboPrincipal Accounting Officer · Principal Accounting Officer at BridgeBio Oncology Therapeutics, filing Form 4 there in the last year
Yong BenChief Med & Dev Officer · Chief Med & Dev Officer at BridgeBio Oncology Therapeutics, filing Form 4 there in the last year
Pedro BeltranPresident and CEO · President and CEO at BridgeBio Oncology Therapeutics, filing Form 4 there in the last year
Bihua ChenDirector and 10% owner · Director and 10% owner at BridgeBio Oncology Therapeutics, filing Form 4 there in the last year